Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian T Ting

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Cell Death & Disease|September 20, 2019
A20 protects cells from TNF-induced apoptosis through linear ubiquitin-dependent and -independent mechanismsDario Priem, Michael Devos, Sarah Druwé, et al.
Cellular & Molecular Immunology|April 26, 2022
IFN-γ<sup>+</sup> cytotoxic CD4<sup>+</sup> T lymphocytes are involved in the pathogenesis of colitis induced by IL-23 and the food colorant Red 40Lili Chen, Zhengxiang He, Bernardo S Reis, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 2021
Immune dysregulation in SHARPIN-deficient mice is dependent on CYLD-mediated cell deathRosalind L Ang, Mark Chan, Diana Legarda, et al.
Cell Reports|June 7, 2016
CYLD Proteolysis Protects Macrophages from TNF-Mediated Auto-necroptosis Induced by LPS and Licensed by Type I IFNDiana Legarda, Scott J Justus, Rosalind L Ang, et al.
Cell Death & Disease|February 7, 2020
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL)Xin Xu, Matko Kalac, Michael Markson, et al.
Molecular Cancer Therapeutics|March 5, 2011
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatmentJianfeng Lu, Donna McEachern, Haiying Sun, et al.
EMBO Reports|July 19, 2008
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral responseConstantin S Friedman, Marie Anne O'Donnell, Diana Legarda-Addison, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
TBK1 and IKKε protect target cells from IFNγ-mediated T cell killing via an inflammatory apoptotic mechanismNicholas D Sun, Allison R Carr, Erica N Krogman, et al.
Cancer Communications (London, England)|January 4, 2025
Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3-dependent necroptotic inflammationZheming Wu, Huaping Xiao, Jake A Kloeber, et al.
Journal of Virology|April 25, 2014
Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent mannerLara Manganaro, Lars Pache, Tobias Herrmann, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Cell Death & Disease|September 20, 2019
A20 protects cells from TNF-induced apoptosis through linear ubiquitin-dependent and -independent mechanismsDario Priem, Michael Devos, Sarah Druwé, et al.
Cellular & Molecular Immunology|April 26, 2022
IFN-γ<sup>+</sup> cytotoxic CD4<sup>+</sup> T lymphocytes are involved in the pathogenesis of colitis induced by IL-23 and the food colorant Red 40Lili Chen, Zhengxiang He, Bernardo S Reis, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 2021
Immune dysregulation in SHARPIN-deficient mice is dependent on CYLD-mediated cell deathRosalind L Ang, Mark Chan, Diana Legarda, et al.
Cell Reports|June 7, 2016
CYLD Proteolysis Protects Macrophages from TNF-Mediated Auto-necroptosis Induced by LPS and Licensed by Type I IFNDiana Legarda, Scott J Justus, Rosalind L Ang, et al.
Cell Death & Disease|February 7, 2020
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL)Xin Xu, Matko Kalac, Michael Markson, et al.
Molecular Cancer Therapeutics|March 5, 2011
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatmentJianfeng Lu, Donna McEachern, Haiying Sun, et al.
EMBO Reports|July 19, 2008
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral responseConstantin S Friedman, Marie Anne O'Donnell, Diana Legarda-Addison, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
TBK1 and IKKε protect target cells from IFNγ-mediated T cell killing via an inflammatory apoptotic mechanismNicholas D Sun, Allison R Carr, Erica N Krogman, et al.
Cancer Communications (London, England)|January 4, 2025
Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3-dependent necroptotic inflammationZheming Wu, Huaping Xiao, Jake A Kloeber, et al.
Journal of Virology|April 25, 2014
Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent mannerLara Manganaro, Lars Pache, Tobias Herrmann, et al.
Pageof 5